Radio-pharmaceutical complexes

Abstract

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.

Description

FIELD OF THE INVENTION[0001]The present invention relates to complexes of thorium isotopes and particularly with complexes of thorium-227 with certain octadentate ligands conjugated to tissue targeting moieties. The invention also relates to the treatment of disease, particularly neoplastic diseases, involving the administration of such complexes.BACKGROUND TO THE INVENTION[0002]Specific cell killing can be essential for the successful treatment of a variety of diseases in mammalian subjects. Typical examples of this are in the treatment of malignant diseases such as sarcomas and carcinomas. However the selective elimination of certain cell types can also play a key role in the treatment of other diseases, especially hyperplastic and neoplastic diseases.[0003]The most common methods of selective treatment are currently surgery, chemotherapy and external beam irradiation. Targeted radionuclide therapy is, however, a promising and developing area with the potential to deliver highly c...

AI Technical Summary

Benefits of technology

The patent text describes a method for making radiopharmaceuticals that saves time and money by not requiring the manufacturer to remove all solvent. The method also reduces waste and contamination. This is important because the radioisotope used in these medications is constantly decaying, so it is best to produce them as quickly as possible. Overall, this method helps to speed up the production process and make the medication more efficiently.

Problems solved by technology

Such a short half-life makes it difficult to produce and distribute radiopharmaceuticals based upon these radionuclides in a commercial manner.

These free radioactive daughters can then cause undesired systemic toxicity.

These are potentially highly advantageous methods, but the administration of liposomes is not desirable in some circumstances and there are many diseases of soft tissue in which the radionuclides cannot be surrounded by a mineralised matrix so as to retain the daughter isotopes.

In the absence of the specific means of retaining the radium daughters of thorium-227 discussed above, the publicly available information regarding radium toxicity made it clear that it was not possible to use thorium-227 as a therapeutic agent since the dosages required to achieve a therapeutic effect from thorium-227 decay would result in a highly toxic and possibly lethal dosage of radiation from the decay of the radium daughters, i.e. there is no therapeutic window.

However, conjugates of suitable chelators with a small targeting peptide or small protein tend to show poor solubility in aqueous systems because the small biomolecule cannot keep the insoluble chelate in solution.

Poor solubility leads to aggregation and precipitation.

Aggregates are unacceptable in a drug preparation to be administered to human subjects and evidently precipitation renders a composition entirely unusable.

This might in some contexts lead to issues with micro aggregation.

In a biological system, such as in a human patient, hydrophobicity in general is associated with undesirable uptake in the liver.

Evidently this is much more serious with highly cytotoxic agents such as alpha-emitters than for typical drug compounds.

Hydrophobicity of the chelator also increases the risk of an immune response, as hydrophobicity facilitates stronger binding of antibodies produced by the host's immune system.

Images